A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results